Bal Pharma logo

Bal Pharma financials and balance sheet

NSE: BALPHARMABSE: 524824Pharmaceuticals & BiotechnologySmall Cap

Last close ₹81.09down ₹3.48 (4.11%)BSE ₹81.60

Share price at the NSE close on 23 Oct 2026. Previous close ₹84.57.

52-week range of traded prices to 23 Oct 2026
₹60.00Low, 30 Mar 2026₹124.60High, 10 Sep 2026
Market cap
₹129 Cr2,779th largest listed
P/E
17.9
P/B
1.6
Dividend yield
1.48%
ROE
9.0%
ROCE
9.3%
Debt to equity
1.94
Volume, NSE
18,242

10 years at a glance

Consolidated: the company and its subsidiaries together. ₹ crore, years to March.Bal Pharma annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
Peak revenue ₹339 Cr, year to Mar 2024A loss in 1 of the 10 years shown

Operating and net margin, per cent

  • Operating margin
  • Net margin

From Apr 2019 leases sit on the balance sheet: rent is charged as depreciation and interest instead, so operating profit and total assets step up with nothing about the business having changed. Borrowings here leave lease liabilities out. Lease payments were 10.7% of operating profit in the first full year.

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue312
  2. Materials and goods−158
  3. Employee costs−66
  4. Other expenses−55
  5. Operating profit32
  6. Depreciation−11
  7. Other income+1.9
  8. One-off items0.0
  9. Finance costs−17
  10. Profit before tax5.9
  11. Tax+0.4
  12. Net profit6.3

What the company owns

  • Plant, investments and other assets₹160 Cr
  • Inventory₹116 Cr
  • Receivables₹94 Cr
  • Cash and bank₹3 Cr
  • Current investments₹2 Cr

What pays for it: net worth and liabilities

  • Borrowings₹160 Cr
  • Owed to suppliers₹89 Cr
  • Net worth₹82 Cr
  • Other liabilities₹45 Cr

Profit and loss

Consolidated, ₹ crore, years to March.Bal Pharma quarterly results

₹ croreMar 2017Mar 2018Mar 2019Mar 2020Filed 11 SepMar 2021Filed 7 JulMar 2022Filed 14 JunMar 2023Filed 30 MayMar 2024Filed 1 AugMar 2025Filed 13 JunMar 2026Filed 22 Jul
Revenue from operations235212225171251281304339303312
221194208166226258279308274280
Materials and goods bought79911784151168173192158158
Employee costs–475150424755606266
Other expenses–484032334351565355
Operating profit before depreciation1417175242325323032
Operating margin6.1%8.2%7.8%2.8%9.8%8.3%8.3%9.3%9.8%10.2%
Materials, % of revenue–46.9%52.1%49.2%60.3%59.6%56.8%56.5%52.1%50.7%
Employee costs, % of revenue–22.3%22.4%29.5%16.7%16.8%18.2%17.8%20.6%21.3%
Other expenses, % of revenue–22.6%17.7%18.6%13.3%15.3%16.8%16.4%17.6%17.8%
Depreciation and amortisation67681099101011
Operating profit after depreciation81111−3151416212021
Other income3212151322
Finance costs891312121012151717
One-off items0000000000
Profit before tax230−14495956
33−2−1−1322−20
Share of profit of joint ventures and associates––––––––0–
202−13563776
Other comprehensive income–––0000000
Total comprehensive income–––−13563877
Net margin0.8%0.2%0.9%−7.5%1.9%2.0%0.9%2.2%2.4%2.0%
Net margin without joint ventures and associates––––––––2.4%–
Materials, employee costs and other expenses are shown for the years they add up to operating expenses; for the year to Mar 2017 they do not, so they are left blank. Belonging to the company's shareholders is left blank for the year to Mar 2018: the filing's earnings per share does not match the profit it states, and cannot be multiplied back into the owners' profit because the earnings per share is under 50 paise, where its rounding to the paisa is too coarse. Belonging to outside owners of subsidiaries is left blank for the year to Mar 2023: the filing states 0 for this share both for the period and for the year so far, which the form also writes for a line it does not fill, while the company's other filings for the same year show it was not 0 over those months.

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2020Filed 11 SepMar 2021Filed 7 JulMar 2022Filed 14 JunMar 2023Filed 30 MayMar 2024Filed 1 AugMar 2025Filed 13 JunMar 2026Filed 22 Jul
45535864697782
52545964697782
Share capital14151516161616
Reserves38394448536166
Belonging to outside owners of subsidiaries−7000000
113105104131140150160
159153166209204220249
34343840473944
Total assets238240262313320336376
7776788585101113
161164185228235235262
Net debt11010198123120140154
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017, Mar 2018 and Mar 2019, so its lines and the ratios worked from it are blank there.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2021Filed 7 JulMar 2022Filed 14 JunMar 2023Filed 30 MayMar 2024Filed 1 AugMar 2025Filed 13 JunMar 2026Filed 22 Jul
2232233292131
2221−14442131
181763528−2
Receivables0−21−10−2
Inventories0−1000−13
Payables0−130−107
Other working capital1834537286
Tax paid002−100
Interest paid0901600
Capital spending0000017
Free cash flow2232233292114
011180−18−21
−3210350−10
Dividends paid0––––2
Shares bought back000200
Shares issued910–00
Net change in cash−10444136431
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020. Dividends paid is left blank for the years to Mar 2022, Mar 2023, Mar 2024 and Mar 2025: the cash-flow statement states no dividends paid, while the company's own dividend record shows one paid in the period, so the line is not given. Shares issued is left blank for the year to Mar 2024: the money stated as raised on shares and other equity instruments is more than three times what the shares issued in the period were worth at its end, so not all of it bought shares and the figure is not given.

Per share

Consolidated, ₹ per share, years to March.Bal Pharma dividend history

₹ per shareMar 2017Mar 2018Mar 2019Mar 2020Filed 11 SepMar 2021Filed 7 JulMar 2022Filed 14 JunMar 2023Filed 30 MayMar 2024Filed 1 AugMar 2025Filed 13 JunMar 2026Filed 22 Jul
Earnings per share₹1.40₹0.10₹1.37–₹3.34₹3.79₹1.67₹4.94₹4.56₹3.95
Diluted earnings per share₹1.40₹0.10₹1.37–₹3.34₹3.71––₹4.56₹3.95
Dividend per share₹1.00₹1.00₹1.00–₹1.00₹1.00₹1.00₹1.20₹1.20₹1.20
Book value per share–––₹36.99₹36.15₹39.55₹40.66₹43.85₹48.63₹51.65
Dividend payout71.4%–73.1%–31.3%26.4%59.9%25.7%26.5%30.4%
Shareholder yield––––−11.5%––––2.0%
Market cap at the year end (₹ crore)12410999457616010514413496
Earnings per share is left blank for the year to Mar 2020: the earnings per share stated does not match any profit the filing states over the shares in issue, and the share count barely moved during the period. Shareholder yield is left blank for the years to Mar 2022, Mar 2023 and Mar 2025: the cash-flow statement states no dividends paid, while the company's own dividend record shows one paid in the period, so the line is not given. Shareholder yield is left blank for the year to Mar 2024: the money stated as raised on shares and other equity instruments is more than three times what the shares issued in the period were worth at its end, so not all of it bought shares and the figure is not given.

Ratios

Consolidated, years to March.Bal Pharma PE ratio and valuation

RatioMar 2017Mar 2018Mar 2019Mar 2020Filed 11 SepMar 2021Filed 7 JulMar 2022Filed 14 JunMar 2023Filed 30 MayMar 2024Filed 1 AugMar 2025Filed 13 JunMar 2026Filed 22 Jul
Revenue growth18.5%−9.9%6.3%−24.0%46.4%12.2%8.2%11.5%−10.7%2.8%
Operating profit growth−4.2%21.9%0.8%−72.8%413.8%−4.0%7.0%25.5%−6.2%7.9%
Net profit growth41.4%−81.0%414.6%––21.1%−54.1%184.3%−3.3%−12.2%
Earnings per share growth–−92.9%1,270.0%––13.5%−55.9%195.8%−7.7%−13.4%
–––−24.6%8.9%10.0%4.3%11.1%9.8%7.9%
––––33.5 pts1.0 pts−5.7 pts6.8 pts−1.3 pts−2.0 pts
From the net margin––––30.8 pts0.5 pts−5.7 pts6.6 pts1.0 pts−1.5 pts
From asset turnover––––2.8 pts0.6 pts−0.2 pts0.1 pts−1.7 pts−0.4 pts
From borrowing––––−0.1 pts−0.1 pts0.2 pts0.1 pts−0.6 pts0.0 pts
Return on capital employed–––−1.8%9.4%8.9%8.2%10.3%8.7%8.6%
Cash conversion––––471.4%561.8%878.9%4,421.3%287.9%487.9%
Interest cover0.91.10.9–1.21.41.31.41.21.2
Debt to equity–––2.491.961.772.062.021.941.94
Receivable days–––1069898113107111110
Inventory days–––294146162207167238269
Payable days–––168114143167149189206
Cash conversion cycle, days–––232130117153125161173
Working capital days–––188129117134123149158
Asset turnover–––0.721.051.121.061.070.920.88
Assets per rupee of net worth–––4.554.514.484.704.764.474.46
Sales per rupee of plant–––2.834.365.064.895.514.274.06
Capital spending to depreciation––––0.000.000.000.000.001.55
Plant being built, % of plant in use–––5.5%0.0%2.9%0.0%0.8%3.9%9.7%
Interest cover is left blank for the year to Mar 2020: operating profit after depreciation is a loss, and a loss covers no interest bill. No balance sheet is on record for the years to Mar 2017, Mar 2018 and Mar 2019, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
1.8%
Cash from operations against operating profit
96.7%
Measure10 years5 years3 years
Revenue growth, yearly rate4.6%4.5%0.8%
Profit growth, yearly rate16.2%5.8%33.9%
Return on equity, average–8.6%9.6%
Return on capital employed, average–8.9%9.2%
Operating margin, average8.0%9.2%9.8%
Net margin, average0.6%1.9%2.2%
Asset turnover, average–1.010.96
Cash conversion cycle, days, average–146153
Interest cover, average1.21.31.3
Debt to equity, average–1.951.97

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations43638131
Cash from investing−9−39−21
Cash from financing2625−10
Capital spending171717
Dividends paid––2
Shares bought back220
Shares issued for cash––0
Borrowings raised232322
Borrowings repaid292913

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9–––––85656
Altman Z-scorePublished threshold 1.81–––1.081.802.111.692.001.741.52
Beneish M-scorePublished threshold −1.78––––−2.23−2.80−2.69−7.12−2.71−2.76
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets––––−7.32−15.00−13.49−101.571.40−1.07
Cash from operations to profit, 3 yearsPublished threshold 0.7 times––––––5.9324.3721.6018.16
Receivables growth less revenue growthOur threshold 0 percentage points––––−10.96−0.1716.60−5.503.45−1.54
Inventory growth less cost-of-goods growthOur threshold 0 percentage points––––−90.2612.2228.60−21.3934.9812.90
Other current assets growth less revenue growthOur threshold 5 per cent of revenue––––−3.12−1.260.16−0.430.536.08
Assets under construction, years of additionsOur threshold 2 years of additions––––0.000.230.000.050.150.44
Effective tax ratePublished threshold 17.16 per cent131.2286.96––−14.8637.8744.8417.70−40.87−6.51
Tax charged less tax paid, % of profitOur threshold 10 percentage points–––––37.8712.051.27−40.87−6.51
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
28 Aug 2026Acuite Ratings & Research Limited (opens in a new tab)Bank Loan RatingsACUITE BBB-Review, Re-affirmStable170
28 Aug 2026Acuite Ratings & Research Limited (opens in a new tab)Bank Loan RatingsACUITE A3Review, Re-affirm19
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.